The “long and winding road” of the disease‐modifying effects of levodopa has not ended yet
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The “long and winding road” of the disease‐modifying effects of levodopa has not ended yet
Authors
Keywords
-
Journal
MOVEMENT DISORDERS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-12-24
DOI
10.1002/mds.27961
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease
- (2019) Constant V.M. Verschuur et al. NEW ENGLAND JOURNAL OF MEDICINE
- When to Start Levodopa Therapy for Parkinson’s Disease
- (2019) Susan Bressman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emerging therapies in Parkinson disease — repurposed drugs and new approaches
- (2019) Ahmad Elkouzi et al. Nature Reviews Neurology
- Does levodopa have a disease‐modifying effect in Parkinson's disease? Evidence from a delayed‐start trial
- (2019) Gaetano Barbagallo et al. MOVEMENT DISORDERS
- Nocebo response in Parkinson's disease: A systematic review and meta-analysis
- (2019) Miguel Leal Rato et al. PARKINSONISM & RELATED DISORDERS
- The Final Nail in the Coffin of Disease Modification for Dopaminergic Therapies
- (2019) Alberto J. Espay JAMA Neurology
- Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration
- (2017) Danielle E Mor et al. NATURE NEUROSCIENCE
- Parkinson disease
- (2017) Werner Poewe et al. Nature Reviews Disease Primers
- A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease
- (2016) David J. M. McGhee et al. BMC Neurology
- Challenges in detecting disease modification in Parkinson's disease clinical trials
- (2016) Dilan Athauda et al. PARKINSONISM & RELATED DISORDERS
- Rational drug discovery design approaches for treating Parkinson’s disease
- (2015) Cornelis J Van der Schyf Expert Opinion on Drug Discovery
- Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics
- (2014) Peter A. LeWitt MOVEMENT DISORDERS
- Levodopa: Effect on cell death and the natural history of Parkinson's disease
- (2014) C. Warren Olanow MOVEMENT DISORDERS
- Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial
- (2013) Anthony HV Schapira et al. LANCET NEUROLOGY
- Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease
- (2011) Jonathan R Evans et al. EXPERT OPINION ON PHARMACOTHERAPY
- The delayed-start study in Parkinson disease: Can't satisfy everyone
- (2010) C. W. Olanow et al. NEUROLOGY
- Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson’s disease: a long-term, retrospective analysis
- (2009) H. Nissinen et al. EUROPEAN JOURNAL OF NEUROLOGY
- The Delayed-Start Study Design
- (2009) Ralph B. D'Agostino NEW ENGLAND JOURNAL OF MEDICINE
- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
- (2009) C. Warren Olanow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics and pharmacodynamics of levodopa
- (2008) John G. Nutt MOVEMENT DISORDERS
- Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
- The history of dopamine and levodopa in the treatment of Parkinson's disease
- (2008) Stanley Fahn MOVEMENT DISORDERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation